Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 3, 2010, Pages 454-463

  Depreter, Flore ^a   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Dry powder inhaler (DPI); Insulin; Lipids; Microparticles; Pulmonary delivery; Spray drying

Indexed keywords

CHOLESTEROL; EXCIPIENT; INSULIN; PHOSPHOLIPID;

ARTICLE; DRUG COATING; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DRY POWDER; GEL FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; LIPID COMPOSITION; MOLECULAR WEIGHT; SPRAY DRYING;

ADMINISTRATION, INHALATION; CHOLESTEROL; DRUG STABILITY; DRY POWDER INHALERS; EXCIPIENTS; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; PARTICLE SIZE; PHOSPHOLIPIDS;

EID: 78549267442     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.08.005     Document Type: Article

References (36)

1. Setter S.M., Iltz J.L., Neumiller J.J., Campbell R.K. Inhaled dry powder insulin for the treatment of Diabetes Mellitus. Clin. Ther. 2007, 29:795-813.
2. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
3. Patton J.S., Bukar J., Nagarajan S. Inhaled insulin. Adv. Drug Deliver. Rev. 1999, 35:235-247.
4. Saudek C.D. Future developments in insulin delivery systems. Diabetes Care 1993, 16(Suppl. 3):122-132.
5. Khafagy E-S, Morishita M., Onuki Y., Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev. 2007, 59:1521-1546.
6. Agu R.U., Ugwoke M.I., Armand M., Kinget R., Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2001, 2:198-209.
7. Scheuch G., Siekneier R. Inhaled insulin - does it become reality?. J. Physiol. Pharmacol. 2008, 59(Suppl. 6):81-113.
8. Gonda I. The ascent of pulmonary drug delivery. J. Pharm. Sci. 2000, 89:940-945.
9. Mastrandrea L.D., Quattrin T. Clinical evaluation of inhaled insulin. Adv. Drug Deliver. Rev. 2006, 58:1061-1075.
10. Bellary S., Barnett A.H. Inhaled insulin: new technology, new possibilities. Int. J. Clin. Pract. 2006, 60(6):728-734.
11. Arnolds S., Heise T. Inhaled insulin. Best Pract. Res. Cl. En. 2007, 21:555-571.
12. Rave K., Bott S., Heinemann L., Sha S., Becker R.H.A., Willavize S.A., Heise T. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005, 28:77-1082.
13. Siekmeier R., scheuch G. Inhaled insulin - does it become reality?. J. Physiol. Pharmacol. 2008, 59(Suppl. 6):81-113.
14. Patton J.S., Bukar J.G., Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 2004, 43:781-801.
15. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24(3):411-437.
16. Adi S., Adi H., Tang P., Traini D., Chan H-k, Young P.M. Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur. J. Pharm. Sci. 2008, 35:12-18.
17. Lohrmann M., Kappl M., Butt H-J, Urbanetz N.A., Lippold B.C. Adhesion forces in interactive mixtures for dry powder inhalers - evaluation of a new measuring method. Eur. J. Pharm. Biopharm. 2007, 67:579-586.
18. Sebti T., Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur. J. Pharm. Biopharm. 2006, 63(1):51-58.
19. Pilcer G., Sebti T., Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm. Res. 2006, 23(5):931-940.
20. Waldrep J.C., Knight C.M., Black M.B., Gilbert B.E., Knight V., Eschenbacher W., Scherer P.W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Chest 1997, 111:316-323.
21. Daugherty A.L., Mrsny R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliver. Rev. 2006, 58:686-706.
22. Hussain A., Arnold J.J., Khan M.A., Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 2004, 94:15-24.
23. Stalh K., Claesson M., Lilliehorn P., Linden H., Backstrom K. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int. J. Pharm. 2002, 233:227-237.
24. Kipp J.E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 2004, 295:269-281.
25. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 2006, 62(1):3-16.
26. Caporal-Gautier J., Nivet J.M., Algranti P., Guilloteau M., Histe M., Lallier M., N'Guyen-Huu J.J., Russotto R. Guide de validation analytique - rapport d'une commission SFSTP. STP Pharma Pract. 1992, 2:205-226.
27. Okumura K., Iwakawa S., Yoshida T., Seki T., Komada F. Intratracheal delivery of insulin: absorption from solution and aerosol by rat lung. Int. J. Pharm. 1992, 88:63-73.
28. Johansson F., Hjertberg E., Eirefelt S., Tronde A., Bengtsson U.H. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 2002, 17:63-71.
29. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 10.1016/j.ijpharm.2010.03.017.
30. Todo H., Okamoto H., Iida K., Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int. J. Pharm. 2001, 220:101-110.
31. Lee H.-K., Kwon J.-H., Park S.-H., Kim C.-W. Insulin microcrystals prepared by the seed zone method. J. Cryst. Growth 2006, 293:447-451.
32. Chew N.Y.K., Tang P., Chan H-K, Raper J.A. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm. Res. 2005, 22(1):148-152.
33. Pilcer G., Vanderbist F., Amghi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int. J. Pharm. 2008, 358:75-81.
34. White S., Bennett D.B., Cheu S., Conley P.W., Guzek D.B., Gray S., Howard J., Malcolmson R., Parker J.M., Roberts P., Sadrzadeh N., Schumacher J.D., Seshadri S., Sluggett G.W., Stevenson C.L., Harper N.J. EXUBERA®: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 2005, 7(6):896-906.
35. Jalalipour M., Gilani K., Tajerzadeh H., Najafabadi A.R., Barghi M. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int. J. Pharm. 2008, 352:209-216.
36. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Preat V., Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 2003, 92(5):938-950.